Sector News

B-MS to build near-$1 billion biologics facility in Ireland

November 14, 2014
Life sciences
Bristol-Myers Squibb has unveiled plans to construct a new biologics manufacturing facility in Ireland which will create up to 400 new jobs as part of a near $1 billion investment.
 
The 30,000-square metre project will house six bioreactors and a purification area as well as office and laboratory space. It will be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant in Cruiserath, Co Dublin.
 
B-MS said the full cost is anticipated to be “comparable to the approximately $900 million investment to construct and operationalise the company’s biologics manufacturing facility in Devens, Massachusetts”. Some 350-400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the plant which is estimated to be operational in 2019.
 
Taoiseach Enda Kenny said the news “is a huge boost to the Irish economy”, noting that 1,000 construction jobs will also be created in the initial phase. He added that the government “has a plan to secure recovery so that Ireland can attract new jobs and investments”.
 
B-MS chief executive Lamberto Andreotti said the investment “reflects the strength of our business and the increasingly important role that biologic medicines will play” in the firm’s future. He noted that “for 50 years, B-MS has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy”.
 
By Kevin Grogan
 
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach